Research map: Real-World Effectiveness of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study

Back to the article

Papers in this map

  1. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance · Anna-Pelagia Magiorakos · 2011 · 14575 citations · Cited by this paper
  2. Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed HIV-1 Infected Adults with TDF-Related Renal or Bone Toxicity · 2026 · Related
  3. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections · Pranita D. Tamma · 2024 · 1157 citations · Cited by this paper
  4. Use of Isavuconazole in the Treatment of Cryptococcosis: A Real-World Case Series · 2026 · Related
  5. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial · Antoní Torres · 2017 · 450 citations · Cited by this paper
  6. Observational, Post-marketing Surveillance of Safety and Effectiveness of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C · 2026 · Related
  7. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused byKlebsiella pneumoniaeCarbapenemase–producingK. pneumoniae · Mario Tumbarello · 2018 · 355 citations · Cited by this paper
  8. Multicenter Real-World Outpatient Use of Intravenous Omadacycline · 2026 · Related
  9. Multidrug-resistant Gram-negative bacterial infections · Nenad Maćešić · 2025 · 311 citations · Cited by this paper
  10. Early Warning and Behavioural Intervention on the Cardiovascular Disease Risk in People Living with HIV: A Multicentre Non-Randomized Controlled Trial · 2026 · Related
  11. Resistance to ceftazidime–avibactam and underlying mechanisms · Yuhang Wang · 2019 · 265 citations · Cited by this paper
  12. HBV Serological Profiles and Vaccination Status in People with HIV in the Transition to a Tenofovir-Sparing Era: Insights from a Large HIV Cohort · 2026 · Related
  13. Klebsiella pneumoniae carbapenemase variants: the new threat to global public health · Li Ding · 2023 · 221 citations · Cited by this paper
  14. Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis · 2026 · Related
  15. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns · Muluneh Assefa · 2022 · 116 citations · Cited by this paper
  16. Hospitalisation Burden of Human Metapneumovirus and Respiratory Syncytial Virus in Adults by Age and Comorbidity Status in Scotland: A Retrospective Analysis · 2026 · Related
  17. The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic · Daniel Reynolds · 2022 · 83 citations · Cited by this paper
  18. Glecaprevir/Pibrentasvir for Acute Hepatitis C Virus Infection in Individuals with a History of Prior Hepatitis C Infection · 2026 · Related
  19. Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points · Antoní Torres · 2019 · 49 citations · Cited by this paper
  20. Clinical and Economic Inpatient Burden of Influenza and Influenza-Like Illness in Germany 2019–2025: Analysis of Nationwide Hospital Data · 2026 · Related
  21. Nationwide Surveillance and Molecular Characterization of Critically Drug-Resistant Gram-Negative Bacteria: Results of the Research University Network Thailand Study · Thitiya Yungyuen · 2021 · 42 citations · Cited by this paper
  22. Risk factors, biomarkers, and mechanisms for persistent inflammation, immunosuppression, and catabolism syndrome (PICS): a systematic review and meta-analysis · Karan R. Chadda · 2024 · 39 citations · Cited by this paper
  23. Global trends of ceftazidime–avibactam resistance in gram-negative bacteria: systematic review and meta-analysis · Yang Wang · 2025 · 35 citations · Cited by this paper
  24. Current and novel therapies for management of Acinetobacter baumannii -associated pneumonia · Aye Mya Sithu Shein · 2024 · 24 citations · Cited by this paper
  25. Clinical and Molecular Characterizations of Carbapenem-Resistant Klebsiella pneumoniae Causing Bloodstream Infection in a Chinese Hospital · Na Zhang · 2022 · 23 citations · Cited by this paper
  26. Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection · Aye Mya Sithu Shein · 2023 · 21 citations · Cited by this paper
  27. Ca-EDTA restores the activity of ceftazidime-avibactam or aztreonam against carbapenemase-producing Klebsiella pneumoniae infections · Dhammika Leshan Wannigama · 2023 · 20 citations · Cited by this paper
  28. Will There Ever Be Cure for Chronic, Life-Changing Colistin-Resistant Klebsiella pneumoniae in Urinary Tract Infection? · Aye Mya Sithu Shein · 2021 · 15 citations · Cited by this paper
  29. Socioeconomic burden of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Korea · Chung-Jong Kim · 2022 · 15 citations · Cited by this paper
  30. State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms · Arsheena Yassin · 2023 · 14 citations · Cited by this paper
  31. Inflammatory Response and Anti-Inflammatory Treatment in Persistent Inflammation-Immunosuppression-Catabolism Syndrome (PICS) · Dacheng Xiong · 2025 · 14 citations · Cited by this paper
  32. Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis · Ryan K. Shields · 2024 · 13 citations · Cited by this paper
  33. Combination Therapy of Ceftazidime/Avibactam for the Treatment of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae: A Multicenter Retrospective Study · Jing Lin · 2023 · 10 citations · Cited by this paper
  34. Efficacy of Ceftazidime-avibactam in treating Gram-negative infections: a systematic review and meta-analysis · Nahal Khoshdel · 2025 · 10 citations · Cited by this paper
  35. Enhancing resistance, but not virulence attributed to the high mortality caused by carbapenem-resistant Klebsiella pneumoniae · Chen Yang · 2024 · 9 citations · Cited by this paper
  36. Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistant Klebsiella pneumoniae · Chang-wei Liu · 2024 · 7 citations · Cited by this paper
  37. Analysis of the etiological characteristics of multidrug-resistant organisms and prognostic factors in ICU patients · Fengxia Du · 2025 · 6 citations · Cited by this paper
  38. Clinical and Microbiological Profile of Hospital-Acquired and Ventilator-Associated Pneumonia in Critically Ill Patients: A Retrospective Observational Study · M.S. Miron · 2026 · 5 citations · Cited by this paper
  39. Efficacy, Safety, and Cost-Effectiveness Analysis of Ceftazidime-Avibactam versus Polymyxin B in the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections: A Target Trial Emulation · Na Hu · 2025 · 4 citations · Cited by this paper

Source: OpenAlex (CC0)